Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kamada Ltd. (KMDA.TA)
Rehovot, IL
Kamada Ltd. is a biopharmaceutical firm specializing in protein therapies derived from blood plasma. Its operations are divided into two primary areas: developing and marketing its own proprietary products, and distributing a portfolio of third-party pharmaceuticals. Under its proprietary segment, Kamada develops and sells treatments such as KAMRAB/KEDRAB for rabies prevention, CYTOGAM for preventing cytomegalovirus in transplant recipients (including kidney, lung, liver, pancreas, heart, and heart/lung), WINRHO SDF for immune thrombocytopenic purpura (ITP) and to prevent Rh sensitization, HEPAGAM B for post-exposure prophylaxis and to stop hepatitis B recurrence after liver transplants, VARIZIG for post-exposure varicella prophylaxis, and GLASSIA, an intravenous therapy for Alpha-1 Antitrypsin Deficiency (AATD). Additional proprietary offerings include KamRho (D) IM for preventing hemolytic disease in newborns, KamRho (D) IV for immune thrombocytopenic purpura, and an antiserum specifically designed to treat snake bites from Vipera palaestinae and Echis coloratus. Through its distribution arm, Kamada provides a diverse portfolio of pharmaceuticals and medical devices. This includes BRAMITOB for chronic pulmonary infections, FOSTER for asthma management, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, the AEROBIKA OPEP device, RUPAFIN for allergic rhinitis and urticaria, IVIG for various immunodeficiency conditions, VARITECT for chickenpox and herpes zoster, ZUTECTRA and HEPATECT CP for hepatitis B, MEGALOTECT CP for cytomegalovirus, RUCONEST for angioedema attacks, heparin sodium injection for treating and preventing thromboembolic disorders, ALBUMIN for blood plasma, Factor VIII for hemophilia A, and Factor IX for hemophilia B. The distributed range also features IXIARO for Japanese encephalitis, VIVOTIF for Salmonella Typhi, PROCYSBI for nephropathic cystinosis, LAMZEDE for alpha-mannosidosis, and ELIGARD for prostate cancer. Kamada employs a multi-channel commercial strategy, utilizing strategic partners to market its products within the United States and relying on a network of distributors for its international sales. Key strategic alliances include collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, the company's headquarters are located in Rehovot, Israel.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.28% | +0.39% | -6.34% | -20.24% | +3.15% | +1.28% | -3.46% | +14.16% | +17.14% | +57.54% | +66.84% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+21.4% ★ Q1'26: +2.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+42.3% ★ Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+5.3% Q1'26: -2.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+14.5% ★ Q1'26: +12.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+11.9% ★ Q1'26: +8.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+6.4% Q1'26: +4.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.26× ★ Q1'26: 0.31× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
70.11M
est: 70.79M (-1.0%)
|
77.49M
est: 77.52M (0.0%)
|
102.83M
est: 98.41M (+4.5%)
|
114.47M
est: 113.18M (+1.1%)
|
127.19M
est: 121.33M (+4.8%)
|
133.25M
est: 134.36M (-0.8%)
|
103.64M
est: 94.28M (+9.9%)
|
129.34M
est: 131.16M (-1.4%)
|
142.52M
est: 144.62M (-1.5%)
|
160.95M
est: 161.20M (-0.2%)
|
195.34M
est: 181.20M (+7.8%)
|
187.89M
185.73M – 189.46M
+3.7% YoY
|
206.52M
199.47M – 211.48M
+9.9% YoY
|
228.85M
223.50M – 232.64M
+10.8% YoY
|
246.03M
240.28M – 250.10M
+7.5% YoY
|
261.30M
255.20M – 265.63M
+6.2% YoY
|
| EBITDA |
-7.73M
est: 9.48M (-181.6%)
|
-1.98M
est: 10.38M (-119.1%)
|
10.97M
est: 13.18M (-16.8%)
|
22.96M
est: 15.16M (+51.5%)
|
27.79M
est: 16.25M (+71.1%)
|
23.73M
est: 17.99M (+31.9%)
|
4.01M
est: 12.63M (-68.3%)
|
16.69M
est: 17.56M (-5.0%)
|
21.53M
est: 19.37M (+11.2%)
|
27.80M
est: 63.81M (-56.4%)
|
44.54M
est: 71.73M (-37.9%)
|
74.38M
73.52M – 75.00M
+3.7% YoY
|
81.75M
78.96M – 83.71M
+9.9% YoY
|
90.59M
88.47M – 92.09M
+10.8% YoY
|
97.39M
95.11M – 99.00M
+7.5% YoY
|
103.44M
101.02M – 105.15M
+6.2% YoY
|
| EBIT |
-10.43M
est: 4.51M (-331.3%)
|
-4.89M
est: 4.94M (-198.9%)
|
7.25M
est: 6.27M (+15.7%)
|
20.51M
est: 7.21M (+184.5%)
|
23.27M
est: 7.73M (+201.2%)
|
18.83M
est: 8.56M (+120.0%)
|
-1.60M
est: 6.00M (-126.7%)
|
4.53M
est: 8.35M (-45.7%)
|
10.06M
est: 9.21M (+9.3%)
|
13.99M
est: 48.41M (-71.1%)
|
28.40M
est: 54.42M (-47.8%)
|
56.43M
55.78M – 56.90M
+3.7% YoY
|
62.02M
59.91M – 63.51M
+9.9% YoY
|
68.73M
67.12M – 69.87M
+10.8% YoY
|
73.89M
72.16M – 75.11M
+7.5% YoY
|
78.48M
76.64M – 79.78M
+6.2% YoY
|
| Net Income |
-11.27M
est: -23.49M (+52.0%)
|
-6.73M
est: -6.58M (-2.4%)
|
6.90M
est: 5.13M (+34.6%)
|
22.30M
est: 17.03M (+30.9%)
|
22.25M
est: 28.52M (-22.0%)
|
17.14M
est: 22.90M (-25.1%)
|
-2.23M
est: 2.19M (-201.8%)
|
-2.32M
est: -2.80M (+17.1%)
|
8.28M
est: 7.16M (+15.6%)
|
14.46M
est: 14.20M (+1.9%)
|
21.86M
est: 21.44M (+2.0%)
|
23.18M
22.47M – 23.67M
+8.1% YoY
|
33.25M
32.24M – 33.97M
+43.5% YoY
|
40.39M
39.16M – 41.26M
+21.5% YoY
|
42.83M
41.53M – 43.75M
+6.0% YoY
|
44.45M
43.10M – 45.41M
+3.8% YoY
|
| SGA |
10.90M
est: 12.65M (-13.9%)
|
10.89M
est: 13.86M (-21.4%)
|
12.67M
est: 17.59M (-28.0%)
|
12.16M
est: 20.23M (-39.9%)
|
13.56M
est: 21.69M (-37.5%)
|
14.66M
est: 24.02M (-39.0%)
|
18.91M
est: 16.85M (+12.2%)
|
28.09M
est: 23.45M (+19.8%)
|
27.45M
est: 25.85M (+6.2%)
|
30.83M
est: 31.32M (-1.5%)
|
36.63M
est: 35.20M (+4.1%)
|
36.50M
36.08M – 36.81M
+3.7% YoY
|
40.12M
38.75M – 41.08M
+9.9% YoY
|
44.46M
43.42M – 45.19M
+10.8% YoY
|
47.80M
46.68M – 48.59M
+7.5% YoY
|
50.76M
49.58M – 51.60M
+6.2% YoY
|
| EPS |
-0.31
est: -0.43 (+27.6%)
|
-0.18
est: -0.12 (-50.2%)
|
0.18
est: 0.09 (+92.5%)
|
0.55
est: 0.31 (+77.2%)
|
0.55
est: 0.52 (+5.8%)
|
0.39
est: 0.42 (-6.6%)
|
-0.05
est: 0.04 (-224.7%)
|
-0.05
est: -0.05 (-1.5%)
|
0.15
est: 0.13 (+19.3%)
|
0.26
est: 0.24 (+6.9%)
|
0.38
est: 0.37 (+3.4%)
|
0.40
0.39 – 0.41
+8.1% YoY
|
0.57
0.55 – 0.58
+43.5% YoY
|
0.69
0.67 – 0.71
+21.5% YoY
|
0.73
0.71 – 0.75
+6.0% YoY
|
0.76
0.74 – 0.78
+3.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-19 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-18 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.03% | 328.2K | 0.35% |
| 2 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.03% | 22.0K | 0.35% |
| 3 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.03% | 130.9K | 0.40% |
| 4 | Avantis International Small Cap Equity ETF AVDS | 0.01% | 27.8K | 0.30% |
| 5 | iShares International Small-Cap Equity Factor ETF ISCF | 0.01% | 32.9K | 0.24% |
| 6 | Dimensional - International Small Cap Value ETF DISV | 0.00% | 118.4K | 0.42% |
| 7 | Dimensional - International Small Cap ETF DFIS | 0.00% | 78.6K | 0.39% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 49.8K | 0.28% |
| 9 | Avantis International Equity ETF AVDE | 0.00% | 3.9K | 0.23% |
| 10 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | — | 0.18% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Amir London | Chief Executive Officer | 714.0K | male |
| Chaime Orlev | Chief Financial Officer | 506.0K | male |
| Eran Nir | Chief Operating Officer | 468.0K | male |
| Boris Gorelik | Vice President of Business Development & Strategic Programs | 422.0K | male |
| Jon R. Knight | Vice President of US Commercial Operations | 308.0K | male |
| David Tsur | Co-Founder & Independent Deputy Chairman of the Board | 252.0K | male |
| Shavit Beladev | Vice President of Kamada Plasma | — | female |
| Hanni Neheman | Vice President of Marketing & Sales | — | female |
| Liron Reshef | Vice President of Human Resources | — | female |
| Nir Livneh | Vice President, General Counsel & Corporate Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KMDA.TA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
